Jihye Paik, PhD

Highlights

101

4 grants

Co-I
Identifying molecular vulnerabilities of ALT-dependent cancers
National Cancer Institute · 2024–2029
R01CA276349-01A1
Sub-PI
FOXO3 dependent proinflammatory transcription program of AD
National Institute on Aging · 2025–2027 · via Columbia University
R21AG085675-01A1
PI
The mechanisms driven by microglial FOXO3 underlying AD progression
Alzheimer's Association National Office · 2023–2026
AARG-NTF-23-1148826
PI
SRA - BL MELANIS CO., LTD
BL PharmTech (Melanis) · 2024–2026Contract
SRA 240554-01

Completed grants (9)

Co-I
Mechanism-Based Targeting of Mantle Cell Lymphoma
National Cancer Institute · 2018–2025
P01CA214274-05
MPI
Longitudinal functional genomics in mantle cell lymphoma therapy and drug resistance
Leukemia & Lymphoma Society · 2018–2023
LLS 180078-01
PI
Mechanisms underlying integrated stress response induced inflammation
National Institute on Aging · 2019–2023
2 R56 AG048284-06,
PI
Targeting molecular vulnerability of ATRX mutant gliomas (YR2 Renewal)
William Rhodes Center for Glioblastoma - Collaborative Research Initiative · 2022–2022
WRC 223372-01
PI
Identification of FOXO1 inhibitor for B cell lymphoma therapy (SRA) - NCE Amendment
FORKHEAD BIOTHERAPEUTICS, INC. · 2019–2022Contract
SRA 201077-01
PI
Targeting Molecular Vulnerabilities of ATRX Mutant Gliomas
William Rhodes Center for Glioblastoma - Collaborative Research Initiative · 2020–2021
WRC 205030-01
PI
The Mechanisms Underlying How Oxidative Stress Influences Neural Stem Cell Fate
National Institute on Aging · 2014–2019
R01AG048284-05
Co-I
Chromatin Remodeling and FOXO in Targeting CDK4 in Mantle Cell Lymphoma
American Society of Hematology Inc · 2017–2019
ASH 170594-01
MPI
Chromatin Remodeling and FOXO in Targeting CDK4 in Mantle Cell Lymphoma
National Cancer Institute · 2018–2018
R01CA219957-01A1

A Promising Solution to a Cancer Drug Resistance Problem
August 3, 2026
A protein that can dial down oxidative stress in cells helps some cancers resist treatment with a widely used class of drugs called BTK inhibitors, according to a study led by investigators at Weill Cornell Medicine.
Discovery Suggests New Way to Target Mantle Cell Lymphoma
November 22, 2022
A form of blood cancer known as mantle cell lymphoma is critically dependent on a protein that coordinates gene expression, such that blocking its activity with an experimental drug dramatically slows the growth of this lymphoma in preclinical tests, according to a study from Weill Cornell Medicine researchers.